OrthoLogic
This article was originally published in The Gray Sheet
Executive Summary
Agrees to pay the Justice Department $1 mil. by Sept. 20 to settle a December 1996 whistle-blower suit under the False Claims Act, the company reports Sept. 2. Filed under seal by a former employee of OrthoLogic before being taken over by the U.S. Attorney's office in May, the suit alleged the firm sold a small number of custom bone growth stimulators not approved by FDA to Medicare and Medicaid beneficiaries and then billed federal Medicare and TRICARE (formerly CHAMPUS) programs and various state Medicaid programs. An FDA warning letter relating to the devices was issued in May 1996 ("The Gray Sheet" June 17, 1996, In Brief). OrthoLogic denies any wrongdoing or liability with respect to the case. Adjudication of the suit exonerates company officers, employees and directors from any civil damages or civil penalties related to the claims. In addition, the HHS Office of the Inspector General will not exclude OrthoLogic from participating in federal health care programs
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.